60 Degrees Pharmaceuticals (SXTP) Competitors $1.76 -0.10 (-5.38%) Closing price 03:58 PM EasternExtended Trading$1.75 -0.01 (-0.57%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SXTP vs. QNTM, TSBX, APLM, RLMD, ABVC, ADXN, OBSV, AYTU, HOTH, and KLTOShould you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include Quantum Biopharma (QNTM), Turnstone Biologics (TSBX), Apollomics (APLM), Relmada Therapeutics (RLMD), ABVC BioPharma (ABVC), Addex Therapeutics (ADXN), ObsEva (OBSV), Aytu BioPharma (AYTU), Hoth Therapeutics (HOTH), and Klotho Neurosciences (KLTO). These companies are all part of the "pharmaceutical products" industry. 60 Degrees Pharmaceuticals vs. Quantum Biopharma Turnstone Biologics Apollomics Relmada Therapeutics ABVC BioPharma Addex Therapeutics ObsEva Aytu BioPharma Hoth Therapeutics Klotho Neurosciences 60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings. Does the media prefer SXTP or QNTM? In the previous week, 60 Degrees Pharmaceuticals had 3 more articles in the media than Quantum Biopharma. MarketBeat recorded 4 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.94 beat 60 Degrees Pharmaceuticals' score of 0.72 indicating that Quantum Biopharma is being referred to more favorably in the news media. Company Overall Sentiment 60 Degrees Pharmaceuticals Positive Quantum Biopharma Positive Which has more volatility & risk, SXTP or QNTM? 60 Degrees Pharmaceuticals has a beta of 4.53, indicating that its share price is 353% more volatile than the S&P 500. Comparatively, Quantum Biopharma has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Do analysts rate SXTP or QNTM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 60 Degrees Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Quantum Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer SXTP or QNTM? 60 Degrees Pharmaceuticals received 1 more outperform votes than Quantum Biopharma when rated by MarketBeat users. CompanyUnderperformOutperform60 Degrees PharmaceuticalsOutperform Votes16.25%Underperform Votes1593.75% Quantum BiopharmaN/AN/A Which has better valuation & earnings, SXTP or QNTM? 60 Degrees Pharmaceuticals has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio60 Degrees Pharmaceuticals$502.41K5.42-$3.77M-$50.41-0.04Quantum BiopharmaN/AN/A-$17.90M-$15.41-0.29 Is SXTP or QNTM more profitable? 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Quantum Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets 60 Degrees PharmaceuticalsN/A N/A -113.43% Quantum Biopharma N/A -84.21%-62.63% Do institutionals and insiders believe in SXTP or QNTM? 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 10.3% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Summary60 Degrees Pharmaceuticals beats Quantum Biopharma on 10 of the 13 factors compared between the two stocks. Remove Ads Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTP vs. The Competition Export to ExcelMetric60 Degrees PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.74M$6.95B$5.65B$8.02BDividend YieldN/A2.72%4.89%4.05%P/E Ratio-0.186.0923.6618.87Price / Sales5.41223.43374.26118.73Price / CashN/A65.6738.0534.64Price / Book-0.186.686.934.23Net Income-$3.77M$139.34M$3.18B$246.92M7 Day Performance16.10%-1.46%6.02%-2.04%1 Month Performance-41.03%-8.12%-0.45%-10.08%1 Year Performance39.69%-4.46%13.15%1.40% 60 Degrees Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTP60 Degrees Pharmaceuticals1.6552 of 5 stars$1.76-5.4%N/A+43.0%$2.59M$502,409.00-0.173Short Interest ↓QNTMQuantum BiopharmaN/A$4.40-4.8%N/AN/A$8.44MN/A-0.29N/ATSBXTurnstone Biologics1.5783 of 5 stars$0.36-3.6%$0.45+25.1%-87.8%$8.32M$19.31M-0.1182Upcoming EarningsShort Interest ↑Gap DownAPLMApollomics2.9432 of 5 stars$7.55+18.2%$200.00+2,549.0%-88.9%$8.21M$1.22M0.0045RLMDRelmada Therapeutics4.3476 of 5 stars$0.27-5.1%$4.25+1,462.5%-95.1%$8.21MN/A-0.0910Upcoming EarningsShort Interest ↓Gap DownABVCABVC BioPharma0.6097 of 5 stars$0.63-1.0%N/A-44.8%$8.21M$509,788.00-0.7430Short Interest ↑ADXNAddex Therapeutics2.7538 of 5 stars$7.50-2.7%$30.00+300.3%-35.3%$7.95M$556,045.00-22.0430Short Interest ↓Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150AYTUAytu BioPharma2.0779 of 5 stars$1.26+0.8%N/A-59.7%$7.77M$77.23M-0.87160Positive NewsHOTHHoth Therapeutics3.3258 of 5 stars$1.10+0.9%$4.00+263.6%-11.2%$7.59MN/A-0.834Analyst ForecastShort Interest ↓KLTOKlotho NeurosciencesN/A$0.28-3.7%N/AN/A$7.55MN/A0.00N/AGap Down Remove Ads Related Companies and Tools Related Companies QNTM Competitors TSBX Competitors APLM Competitors RLMD Competitors ABVC Competitors ADXN Competitors OBSV Competitors AYTU Competitors HOTH Competitors KLTO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SXTP) was last updated on 3/13/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
